Non-mycosis Fungoides Cutaneous T-cell LymphomasNon-mycosis Fungoides Cutaneous T-cell Lymphomas
Primary cutaneous CD30+ T-cell lymphoproliferative disorders and their differential diagnosis are highlighted in this report from the European Society for Hematopathology. American Journal of Clinical Pathology
Photochem. Photobiol. Sci., 2018, Accepted Manuscript DOI: 10.1039/C8PP00170G, PerspectiveFranz Trautinger Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas arising in the skin. Mycosis fungoides (MF), the most common variant, is characterised by clonal proliferation of skin residing... The content of this RSS Feed (c) The Royal Society of Chemistry
This article is protected by copyright. All rights reserved. PMID: 30298903 [PubMed - as supplied by publisher]
Establishing a registry and prognostic index for mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), and Szary syndrome, a rare type of CTCL, is important to improve the mana... Author: VJHemOnc Added: 10/02/2018
A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides and Szary syndrome, the most common types of cu... Author: VJHemOnc Added: 10/02/2018
This article is protected by copyright. All rights reserved. PMID: 30269331 [PubMed - as supplied by publisher]
Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.
AbstractCutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphomas that are characterized by primary skin involvement. Mycosis fungoides (MF) and S ézary syndrome (SS), the two most common subtypes of CTCL, can be difficult to manage clinically as there are few effective treatment options available. Recently, histone deacetylase inhibitors (HDACi) have emerged as promising therapies with favorable adverse effect profiles, compared with traditi onal chemotherapies. In this article, we review the published literature to evaluate the role of HDACi in the treatment of CTCL. Specifically, we (1) briefly di...
Aim: Mycosis Fungoides (MF) is a cutaneous T-cell lymphoma variant that, in early disease, is often difficult to differentiate from inflammatory dermatoses. Mild spongiosis may be present, but significant spongiosis is exceedingly rare. In a series of 745 biopsies of early/patch MF, only 4% were found to have marked spongiosis. Accepted criteria to confirm MF include epidermotropism of atypical lymphocytes without spongiosis, or epidermotropism out of proportion to any spongiosis that may be present.
We present two patients with indolent cutaneous T-cell lymphoma (CTCL) who had a clonal leukemic fraction of sCD3-, cCD3+, sCD4+ T-cell cells with less cell atypia. The cutaneous lesion of case 1 (60s, female) showed epidermotropic and perivascular infiltration of cCD3+, CD4+ T-cells, the features of which were consistent with those of mycosis fungoides, while in case 2 (50s, male), the diagnosis of CTCL was not confirmed histologically.
Mycosis fungoides is a primary cutaneous T cell lymphoma with unfavorable prognosis for the advanced stages of the disease. Refractory disease and advanced-staged disease require systemic therapy.